Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.11.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ction 13(a) of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoi |
| 09.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appoin |
| 11.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Original 8-K. The disclosure contained in Item 5.02 of the Original 8-K is hereby supplemented and amended by the |
| 05.04.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | t on Form 8-K in accordance with Instruction 2 to Item 5.02 of Form 8-K. In connection with the Company’s termination of |
| 09.01.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | n 13(a) of the Exchange Act. ☒ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointme |
Stammdaten
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Unternehmen & Branche
| Name | Bioventus Inc. |
|---|---|
| Ticker | BVS |
| CIK | 0001665988 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 665,9 Mio. USD |
| Beta | 0,69 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 568,087,000 | 22,732,000 | 0.33 | 683,559,000 | 184,105,000 |
| 2025-09-27 | 10-Q | 138,651,000 | 3,155,000 | 0.05 | 701,593,000 | 166,096,000 |
| 2025-06-28 | 10-Q | 147,660,000 | 7,459,000 | 0.11 | 706,788,000 | 161,242,000 |
| 2025-03-29 | 10-Q | 123,876,000 | -2,637,000 | -0.04 | 691,414,000 | 148,144,000 |
| 2024-12-31 | 10-K | 573,280,000 | -36,125,000 | -0.56 | 727,956,000 | 147,940,000 |
| 2024-09-28 | 10-Q | 138,964,000 | -5,165,000 | -0.08 | 769,492,000 | 148,738,000 |
| 2024-06-29 | 10-Q | 151,217,000 | -25,682,000 | -0.40 | 792,173,000 | 150,935,000 |
| 2024-03-30 | 10-Q | 129,457,000 | -4,890,000 | -0.08 | 794,238,000 | 171,276,000 |
| 2023-12-31 | 10-K | 512,345,000 | -156,230,000 | -2.49 | 810,910,000 | 173,591,000 |
| 2023-09-30 | 10-Q | 120,794,000 | -7,303,000 | -0.12 | 811,104,000 | 177,529,000 |
| 2023-07-01 | 10-Q | 137,069,000 | -3,681,000 | -0.06 | 836,962,000 | 183,195,000 |
| 2023-04-01 | 10-Q | 119,059,000 | -139,150,000 | -2.24 | 887,404,000 | 188,511,000 |
| 2022-12-31 | 10-K | 512,117,000 | -158,704,000 | -2.59 | 1,372,649,000 | 325,238,000 |
| 2022-10-01 | 10-Q | 128,662,000 | -108,245,000 | -1.76 | 1,398,022,000 | 343,397,000 |
| 2022-07-02 | 10-Q | 140,331,000 | -7,252,000 | -0.11 | 1,208,776,000 | 447,981,000 |
| 2022-04-02 | 10-Q | 117,290,000 | -11,277,000 | -0.19 | 1,197,137,000 | 449,776,000 |
| 2021-12-31 | 10-K | 430,898,000 | -6,602,000 | -0.15 | 1,225,862,000 | 458,924,000 |
| 2021-10-02 | 10-Q | 108,890,000 | -1,071,000 | -0.03 | 654,790,000 | 152,503,000 |
| 2021-07-03 | 10-Q | 109,816,000 | -4,126,000 | -0.10 | 646,636,000 | 141,557,000 |
| 2021-04-03 | 10-Q | 81,778,000 | -1,041,000 | -0.02 | 643,075,000 | 142,390,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-11 | McMurry-Heath Michelle | Director | Open Market Sale | -12,000 | 8.79 | -105,439.20 | -101,3% | |
| 2025-12-04 | NOHRA GUY P | Director | Open Market Sale | -10,000 | 7.57 | -75,658.00 | -72,7% | |
| 2025-11-07 | McMurry-Heath Michelle | Director | Open Market Sale | -17,701 | 7.42 | -131,254.69 | -126,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.